Parallel Advisors’s Dare Bioscience DARE Stock Holding History

Parallel Advisors’s Portfolio DARE Stock Details DARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,405	Closed	-$4.64K	–	3866
2025 Q4	$4.64K	Buy	+2,405	New	+$4.8K	﹤0.01%	2869

Other funds holding DARE

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parallel Advisors's DARE Position: Q1 2026 in Review

Parallel Advisors sold out of Dare Bioscience (DARE) in Q1 2026, closing a stake of 2,405 shares — an estimated $4.64K sold.

Parallel Advisors first reported a position in DARE in Q4 2025 and held it in 1 quarter. The position peaked at $4.64K in Q4 2025. 25 funds tracked by Wall St. Rank hold DARE as of Q1 2026.

Parallel Advisors reported no remaining Dare Bioscience position as of Q1 2026 after selling out during the quarter.
Parallel Advisors sold 2,405 Dare Bioscience shares in Q1 2026, an estimated $4.64K.
Parallel Advisors first reported a position in Dare Bioscience in Q4 2025 and held it in 1 quarter.
Parallel Advisors's Dare Bioscience position peaked at $4.64K in Q4 2025.
25 funds tracked by Wall St. Rank held Dare Bioscience as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.